Values as of: 2025-06-05
COMMON STOCK | Biotechnology |
Last Closing
USD 19.94Change
-0.39 (-1.92)%Market Cap
USD 4.74BVolume
1.56MAnalyst Target
USD 9.83Verdict
Verdict
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Company Website : https://www.admabiologics.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
-2.03 (-0.46%) |
USD 128.84B |
| REGN | Regeneron Pharmaceuticals Inc |
-1.86 (-0.38%) |
USD 65.38B |
| ARGX | argenx NV ADR |
+7.09 (+1.24%) |
USD 34.54B |
| ALNY | Alnylam Pharmaceuticals Inc |
+2.69 (+0.88%) |
USD 32.75B |
| ONC | BeiGene, Ltd. |
-1.27 (-0.49%) |
USD 27.70B |
| RPRX | Royalty Pharma Plc |
+0.31 (+0.93%) |
USD 18.35B |
| SMMT | Summit Therapeutics PLC |
+0.17 (+0.87%) |
USD 13.53B |
| INSM | Insmed Inc |
-0.95 (-1.29%) |
USD 11.84B |
| INCY | Incyte Corporation |
-0.18 (-0.27%) |
USD 11.42B |
| BMRN | Biomarin Pharmaceutical Inc |
-0.84 (-1.50%) |
USD 11.29B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| PINK | Simplify Exchange Traded .. | 5.71 % | 0.00 % |
-0.12 (-0.18%) |
USD 0.13B |
| SAWS | AAM Sawgrass U.S. Small C.. | 3.46 % | 0.00 % |
-0.04 (-0.18%) |
USD 0.99M |
| DWAS | Invesco DWA SmallCap Mome.. | 1.49 % | 0.60 % |
+0.14 (+-0.18%) |
USD 0.64B |
| PSCH | Invesco S&P SmallCap Heal.. | 0.00 % | 0.29 % |
+0.11 (+-0.18%) |
USD 0.15B |
| AFSM | First Trust Active Factor.. | 0.00 % | 0.00 % |
N/A |
USD 0.03B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 16.27% | 77% | C+ | 83% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 16.27% | 77% | C+ | 83% | B | ||
| Trailing 12 Months | |||||||
| Capital Gain | 88.47% | 91% | A- | 92% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 88.47% | 91% | A- | 92% | A | ||
| Trailing 5 Years | |||||||
| Capital Gain | 570.25% | 98% | N/A | 97% | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 570.25% | 98% | N/A | 97% | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 101.26% | 86% | B+ | 93% | A | ||
| Dividend Return | 101.26% | 86% | B+ | 93% | A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 127.32% | 31% | F | 16% | F | ||
| Risk Adjusted Return | 79.53% | 99% | N/A | 92% | A | ||
| Market Capitalization | 4.74B | 95% | A | 88% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
